STOCK TITAN

Insider buy: Camp4 Therapeutics Corp (CAMP) CMO adds 6,551 shares

(Neutral)
(Positive)
Form Type
4

Rhea-AI Filing Summary

Camp4 Therapeutics Corp Chief Medical Officer Yuri Maricich purchased 6,551 shares of common stock on August 3, 2026 in the second closing of a private placement at $1.65 per share under a Securities Purchase Agreement. After this transaction, he directly holds 12,611 common shares.

Positive

  • None.

Negative

  • None.
Insider Maricich Yuri
Role Chief Medical Officer
Bought 6,551 shs ($11K)
Type Security Shares Price Value
Purchase Common Stock F1 6,551 $1.65 $11K
Holdings After Transaction: Common Stock — 12,611 shares (Direct)
Footnotes (1)
  1. F1. On August 3, 2026, the reporting person acquired shares in the second closing of a private placement by the Issuer pursuant to the terms of a Securities Purchase Agreement, dated as of September 9, 2025, as amended on August 3, 2026, by and among the Issuer and certain institutional investors and certain directors, employees, and consultants, at a purchase price of $1.65 per share.
Shares purchased 6,551 shares Common stock acquired on August 3, 2026 in a private placement
Purchase price $1.65 per share Price paid in the August 3, 2026 private placement
Shares held after purchase 12,611 shares Direct Camp4 common stock holdings following the reported transaction
private placement financial
"acquired shares in the second closing of a private placement by the Issuer"
A private placement is a sale of securities directly to a selected group of investors, typically institutions or accredited investors, instead of through a public offering. It lets a company raise money faster and with fewer regulatory steps; for existing shareholders it matters because the newly issued shares, often sold at a discount, increase the share count and can dilute their ownership.
Securities Purchase Agreement financial
"pursuant to the terms of a Securities Purchase Agreement, dated as of September 9, 2025"
A securities purchase agreement is a written contract between a buyer and a seller outlining the terms for buying or selling financial assets such as stocks or bonds. It specifies details like the price, quantity, and conditions of the transaction, similar to a shopping list with agreed-upon terms. For investors, it provides clarity and legal protection when transferring ownership of these financial instruments.
institutional investors financial
"by and among the Issuer and certain institutional investors and certain directors"
Institutional investors are large organizations, like pension funds, insurance companies, and mutual funds, that invest huge amounts of money on behalf of many people. Their decisions can influence the economy because they buy and sell big chunks of stocks, bonds, or other assets. They matter because their actions can affect market prices and trends.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
Learn about SEC filing dates

FAQ

What insider transaction did CAMP report for Chief Medical Officer Yuri Maricich?

Yuri Maricich, Camp4 Therapeutics Corp’s Chief Medical Officer, bought 6,551 common shares on August 3, 2026. The shares were acquired in the second closing of a private placement at $1.65 per share under a Securities Purchase Agreement.

At what price were the new CAMP shares purchased by the chief medical officer?

The chief medical officer purchased the new CAMP shares at $1.65 per share. The acquisition occurred in the second closing of a private placement pursuant to a Securities Purchase Agreement involving institutional investors and company insiders.

How many CAMP shares does the Camp4 CMO hold after this Form 4 transaction?

Following the reported transaction, the Camp4 Therapeutics Corp CMO directly holds 12,611 common shares. This reflects his August 3, 2026 purchase of 6,551 shares in a private placement conducted under a previously executed Securities Purchase Agreement.

Was the latest CAMP insider share purchase made under a Rule 10b5-1 trading plan?

The reported CAMP insider purchase was not made under a Rule 10b5-1 trading plan. The filing’s Rule 10b5-1 checkbox is explicitly unchecked, and the footnote instead ties the transaction to a negotiated Securities Purchase Agreement for a private placement.

What is the context of the private placement referenced in CAMP’s Form 4 filing?

The Form 4 notes that shares were acquired in the second closing of a private placement under a Securities Purchase Agreement dated September 9, 2025, amended August 3, 2026, involving the issuer, institutional investors, and certain directors, employees, and consultants.
SEC Form 4
FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0287
Estimated average burden
hours per response:0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Maricich Yuri

(Last)(First)(Middle)
C/O CAMP4 THERAPEUTICS CORPORATION
ONE KENDALL SQ., BLDG 1400 WEST, 3RD FL.

(Street)
CAMBRIDGE MASSACHUSETTS 02139

(City)(State)(Zip)

UNITED STATES

(Country)
2. Issuer Name and Ticker or Trading Symbol
Camp4 Therapeutics Corp [ CAMP ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
Director10% Owner
XOfficer (give title below)Other (specify below)
Chief Medical Officer
2a. Foreign Trading Symbol
3. Date of Earliest Transaction (Month/Day/Year)
08/03/2026
6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeVAmount(A) or (D)Price
Common Stock08/03/2026P6,551A$1.65(1)12,611D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Explanation of Responses:
1. On August 3, 2026, the reporting person acquired shares in the second closing of a private placement by the Issuer pursuant to the terms of a Securities Purchase Agreement, dated as of September 9, 2025, as amended on August 3, 2026, by and among the Issuer and certain institutional investors and certain directors, employees, and consultants, at a purchase price of $1.65 per share.
Remarks:
/s/ Kelly Gold, as Attorney-in-Fact08/05/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)